1,3-二氢-1,3-二氧代-2H-异吲哚-2-乙烷磺酸 | 4443-24-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 1,3-二氢-1,3-二氧代-2H-异吲哚-2-乙烷磺酸
• 中文别名: 1,3-二氧代-2-异吲哚啉乙磺酸钠盐；1,3-二氧代-2-异吲哚啉乙磺酸
• 英文名称: NCS 731
• 英文别名: N,N-phthaloyl-taurine；N,N-Phthaloyl-taurin；2-(1,3-Dioxoisoindolin-2-yl)ethanesulfonic acid；2-(1,3-dioxoisoindol-2-yl)ethanesulfonic acid
• CAS: 4443-24-7
• 化学式: C₁₀H₉NO₅S
• 分子量: 255.251
• InChiKey: GSLVEXPADWBUAC-UHFFFAOYSA-N

物化性质

• 密度：
  1.608

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 储存条件：
  存储条件：2-8°C，干燥且密封。

反应信息

• 作为反应物：
  描述：

  1,3-二氢-1,3-二氧代-2H-异吲哚-2-乙烷磺酸 在 五氯化磷 、 氨 作用下， 以 四氢呋喃 、 苯 为溶剂， 生成 2-(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)乙烷磺酰胺
  参考文献：
  名称：

  Synthesis and biological properties of new 1β-methylcarbapenems

  摘要：

  The synthesis and biological activity of the novel series of 1 beta-methylcarbapenems, 1 and 2 were described. Most compounds displayed high potent antibacterial activity. The best compound in this series, 2a (IH201; R-2=NH2) showed an excellent and a broad spectrum as well as high renal DHP-I stability. It also possessed good in vivo efficacy and high safety. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00270-4
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硝酸 作用下， 生成 1,3-二氢-1,3-二氧代-2H-异吲哚-2-乙烷磺酸
  参考文献：
  名称：

  Gabriel, Chemische Berichte, 1891, vol. 24, p. 1117

  摘要：

  DOI：

文献信息

• Process for production of delta-9- tetrahydrocannabinol
  申请人：Burdick C. David

  公开号：US20070093665A1

  公开（公告）日：2007-04-26

  The present invention relates to a process for preparation of a delta-9-tetrahydrocannabinol compound or derivative thereof involving treating a first intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the delta-9-tetrahydrocannabinol compound or derivative thereof. Another aspect of the present invention relates to a process for preparation of a cannabidiol or cannabidiolate compound involving reacting a first starting compound with a second starting compound in the presence of a metal triflate catalyst, under conditions effective to form the cannabidiol or cannabidiolate compound. The present invention also relates to a compound of the formula: where R 8 , R 9 , and R 10 are the same or different and independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or halo, with R 1 , R 2 , and R 3 defined herein.

  本发明涉及一种制备Δ-9-四氢大麻酚化合物或其衍生物的方法，涉及将第一中间化合物与基于有机铝的Lewis酸催化剂处理，在有效条件下产生Δ-9-四氢大麻酚化合物或其衍生物。本发明的另一个方面涉及一种制备大麻二酚或大麻二酚盐化合物的方法，涉及在金属三氟甲磺酸盐催化剂存在下，将第一起始化合物与第二起始化合物反应，在有效条件下形成大麻二酚或大麻二酚盐化合物。本发明还涉及一个化合物，其化学式为：其中R8、R9和R10相同或不同，并且独立地选自H、取代或未取代的烷基、取代或未取代的芳基、取代或未取代的杂环芳基或卤素，其中R1、R2和R3在此定义。
• Novel piperazine derivatives
  申请人：——

  公开号：US20020107255A1

  公开（公告）日：2002-08-08

  A compound of the formula 1 or the pharmaceutically acceptable salt thereof; wherein a, b, c, d, e, j, R 1 , R 2 , R 3 , and R 4 are as defined above useful to treat inflammation and other immune disorders.

  该化合物的分子式为1，或其药用盐；其中a、b、c、d、e、j、R1、R2、R3和R4如上所定义，用于治疗炎症和其他免疫性疾病。
• Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1724269A1

  公开（公告）日：2006-11-22

  The present invention relates to compounds of the formula I, in which R1; R2; R3; V; G1 and G2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa, and can in general be applied in conditions in which an undesired activity of factor Xa is present or for the cure or prevention of which an inhibition of factor Xa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及具有以下式I的化合物，其中R1; R2; R3; V; G1和G2具有声明中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血凝酶因子Xa的可逆抑制剂，通常可应用于存在血凝酶因子Xa不良活性的情况或者预期抑制血凝酶因子Xa以治疗或预防的情况。此外，该发明还涉及制备具有式I的化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。
• Processes for the production of cannabidiol derivatives and intermediates thereof
  申请人：Albany Molecular Research, Inc.

  公开号：EP2578561A1

  公开（公告）日：2013-04-10

  This invention relates to a process for the preparation of a product compound of the formula: wherein: R1 is H, substituted or unsubstituted alkyl, carboxylic ester, or acyl; R2 is H, OH, protected hydroxyl, substituted or unsubstituted alkyl, alkenyl, alkynyl, acyl, aryl, or heteroaryl; R3 is H, substituted or unsubstituted alkyl, carboxylic ester, or acyl; R4 is H, substituted or unsubstituted alkyl, silyl, hetero-substituted or unsubstituted acyl, alkylsulfonyl, arylsulfonyl, alkylphosphoryl, or arylphosphoryl; and R6 is H, substituted or unsubstituted alkyl, silyl, hetero-substituted or unsubstituted acyl, alkylsulfonyl, arylsulfonyl, alkylphosphoryl, or arylphosphoryl.

  本发明涉及一种制备公式化合物的过程：其中：R1为氢，取代或未取代烷基，羧酸酯或酰基；R2为氢，羟基，保护羟基，取代或未取代烷基，烯基，炔基，酰基，芳基或杂环芳基；R3为氢，取代或未取代烷基，羧酸酯或酰基；R4为氢，取代或未取代烷基，硅基，杂原子取代或未取代酰基，烷基磺酰基，芳基磺酰基，烷基磷酰基或芳基磷酰基；R6为氢，取代或未取代烷基，硅基，杂原子取代或未取代酰基，烷基磺酰基，芳基磺酰基，烷基磷酰基或芳基磷酰基。
• Sulfonyl esters of tetrahydrocannabinol and derivatives thereof
  申请人：Albany Molecular Research, Inc.

  公开号：EP2578577A1

  公开（公告）日：2013-04-10

  This invention relates to a compound of the formula: wherein: R1 is H, substituted or unsubstituted alkyl, carboxylic ester, or acyl; R2 is H, OH, protected hydroxyl, substituted or unsubstituted alkyl, alkenyl, alkynyl, acyl, aryl, or heteroaryl; R3 is H, substituted or unsubstituted alkyl, carboxylic ester, or acyl; R8, R9, and R10 are the same or different and independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or halo; and R8 and R9; R8 and R10; or R9 and R10; or R8, R9, and R10 can together result in the formation of a cyclic moiety.

  本发明涉及一种化合物，其结构式为：其中：R1为H、取代或未取代的烷基、羧酸酯或酰基；R2为H、OH、保护的羟基、取代或未取代的烷基、烯基、炔基、酰基、芳基或杂环芳基；R3为H、取代或未取代的烷基、羧酸酯或酰基；R8、R9和R10相同或不同且独立地选自以下组中的一种：H、取代或未取代的烷基、取代或未取代的芳基、取代或未取代的杂环芳基或卤素；且R8和R9、R8和R10、或R9和R10；或R8、R9和R10可以共同形成环状基团。